Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:02 2025-07-08 EDT			After hours 16:18:00
81.37 ^USD	+0.58%		81.76	+0.48%

01:51pm	Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	MT
01:51pm	Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	MT

Merck Says FDA Approves Keytruda for Head and Neck Cancer With PD-L1 Expression

Published on 2025-06-13 at 07:19

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Merck & Co., Inc.

Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	01:51pm	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	01:51pm	MT
Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025	08:36am	CI
Certara Expands Clinical Technology Collaboration With Merck	08:24am	MT
Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports	07-03	RE
Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports	07-03	RE
Merck's HPV Vaccine Gardasil Remains Key Driver Ahead of Q2 Results, UBS Says	07-02	MT
FDA Grants Priority Review for WinrevaIR (sotatercept-csrk) to Update Label Based on Results from Zenith Trial of Merck & Co., Inc	07-02	CI
Organon abandons endometriosis pain drug development after trial failure	07-02	RE
Merck: FDA priority review status for Winrevair	07-02	CF
Merck Says FDA Granted Priority Review to New Supplemental Biologics License Application for Winrevair	07-02	MT
Merck & Co., Inc.(NYSE:MRK) added to Russell 3000 Value Index	06-30	CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 1000 Dynamic Index	06-30	CI
Merck & Co., Inc.(NYSE:MRK) added to Russell 1000 Value-Defensive Index	06-30	CI
Merck & Co., Inc.(NYSE:MRK) added to Russell 1000 Value Index	06-30	CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 1000 Growth-Defensive Index	06-30	CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 3000E Growth Index	06-30	CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 3000 Growth Index	06-30	CI
Merck & Co., Inc.(NYSE:MRK) added to Russell Top 200 Value Index	06-30	CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell Top 200 Growth Index	06-30	CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 1000 Growth Index	06-30	CI
Merck & Co., Inc.(NYSE:MRK) added to Russell 3000E Value Index	06-29	CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell Top 200 Growth Benchmark	06-29	CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 3000E Growth Benchmark	06-29	CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 3000 Growth Benchmark	06-29	CI

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (67%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (22.1%); - sale of animal health products (9.4%); - other (1.5%). Net sales are distributed geographically as follows: the United States (47.4%), Europe/Middle East/Africa (22%), China (11.3%), Japan (5.3%), Asia/Pacific (5.4%), Latin America (5.1%) and other (3.5%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

07-17 - Investor Meeting

More about the company